16:19 , Oct 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest CAR T cells targeting ALCAM and HER2 could help treat brain cancer. The cells are generated by conjugating T cells expressing HER2-targeting CARs to a construct consisting of pentamers...
00:07 , Sep 28, 2018 |  BC Innovations  |  Tools & Techniques

Deconstructing tox in immuno-oncology

The best route to improving preclinical toxicity in immunotherapies could lie in reverse translation, feeding clinical data back into the preclinical space to inform model development, rather than trying to guess...
19:32 , Sep 7, 2018 |  BC Week In Review  |  Company News

Atara partners with Moffitt Cancer Center to develop CAR T therapies

Atara Biotherapeutics Inc. (NASDAQ:ATRA) partnered with H. Lee Moffitt Cancer Center and Research Institute (Tampa, Fla.) to develop multi‑targeted CAR T immunotherapies to treat cancers with diverse cell types that often become resistant to treatment,...
22:56 , Sep 5, 2018 |  BC Extra  |  Preclinical News

Two papers open door to T cell brain entry for glioblastoma therapy

Two new studies have proposed solutions to different barriers that prevent T cells from entering the brain to attack glioblastoma. Glioblastoma patients often have low T cell counts, and their tumors’ ability to evade immune...
02:36 , Aug 24, 2018 |  BC Innovations  |  Targets & Mechanisms

Computing checkpoints

After 25 years as a discovery company, Compugen Ltd. is about to enter the clinic for the first time with a first-in-class mAb against a new checkpoint target. The target’s expression on adaptive immune cells,...
22:15 , Aug 2, 2018 |  BC Innovations  |  Tools & Techniques

Model firsts

By combining disparate data into coherent mechanistic models, quantitative systems pharmacology is becoming a key tool for picking the right dose for first-in-human trials and other early make-or-break decisions. Advocates see it as part of...
23:26 , Mar 21, 2018 |  BioCentury  |  Finance

Seeking domestic partners

The syndicate behind TCR2 Therapeutics Inc.’s $125 million series B round includes a bevy of Chinese investors who could provide access to development and manufacturing partners in China. 6 Dimensions Capital and Curative Ventures led...
18:21 , Feb 28, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy CAR T cells engineered to target soluble TGFβ could be useful for treating solid tumors with immunosuppressive microenvironments driven by the cytokine. The CAR T cells are engineered to express a CAR...
01:06 , Jan 6, 2018 |  BioCentury  |  Strategy

CAR dealing

Johnson & Johnson’s deal with Legend Biotech will net the pharma both an anti-BCMA CAR T therapy and a partner to help shape its cell therapy strategy. J&J chose the Chinese company’s LCAR-B38M as its...
04:17 , Dec 8, 2017 |  BC Week In Review  |  Financial News

Atox Bio raises $30M series F

On Dec. 4, Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led by new investor Arix Bioscience plc (LSE:ARIX), which contributed $8 million. Fellow new investors Adams Street Partners...